Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Denton (London, United Kingdom), C. Lin (South San Francisco, United States of America), J. Goldin (Los Angeles, United States of America), G. Kim (Los Angeles, United States of America), M. Kuwana (Tokyo, Japan), Y. Allanore (Paris, France), A. Batalov (Plovdiv, Bulgaria), I. Butrimiene (Vilnius, Lithuania), P. Carreira (Madrid, Spain), M. Matucci-Cerinic (Florence, Italy), O. Distler (Zurich, Switzerland), D. Martinovic Kaliterna (Split, Croatia), C. Mihai (Bucharest, Romania), M. Mogensen (Copenhagen, Denmark), M. Olesinska (Warsaw, Poland), J. Pope (London, Canada), G. Riemekasten (Berlin, Germany), T. Rodriguez-Reyne (Mexico City, Mexico), M. Santos (Almada, Portugal), J. Van Laar (Utrecht, Netherlands), H. Spotswood (Welwyn Garden City, United Kingdom), J. Siegel (South San Francisco, United States of America), A. Jahreis (South San Francisco, United States of America), D. Furst (Los Angeles, United States of America), D. Khanna (Ann Arbor, United States of America). Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc). 1883

Member's Comments

No comment yet.

Related content which might interest you: Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial Source: Eur Respir J 2008; 31: 1189-1196 Year: 2008 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-controlled trials Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Late Breaking Abstract - Safety of combined pirfenidone (PFD) and nintedanib (NIN) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Late-breaking findings in pulmonary diseases Year: 2017 Auto-antibody subsets and extent of pulmonary fibrosis in systemic sclerosis (SSc) Source: Eur Respir J 2005; 26: Suppl. 49, 202s Year: 2005 Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006 Management of PAH associated with systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD): immunosuppressive therapy (IT) alone or combined with PAH specific therapies? Source: Eur Respir J 2007; 30: Suppl. 51, 344s Year: 2007 Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003